By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Ascites. According to news reporting originating from Bethesda, Maryland, by NewsRx correspondents, research stated, "Blood contamination, such as bloody ascites or hemorrhages during surgery, is a potential hazard for clinical application of fluorescence imaging. In order to overcome this problem, we investigate if fluorescence-lifetime imaging helps to overcome this problem."
Our news editors obtained a quote from the research from National Cancer Institute, "Samples were prepared at concentrations ranging 0.3-2.4m and mixed with 0-10% of blood. Fluorescence intensities and lifetimes of samples were measured using a time-domain fluorescence imager. Ovarian cancer SHIN3 cells overexpressing the D-galactose receptor were injected into the peritoneal cavity 2.5weeks before the experiments. Galactosyl serum albumin-rhodamine green (GSA-RhodG), which bound to the D-galactose receptor and was internalized thereafter, was administered intraperitoneally to peritoneal ovarian cancer-bearing mice with various degrees of bloody ascites. In vitro study showed a linear correlation between fluorescence intensity and probe concentration (r(2) >0.99), whereas the fluorescence lifetime was consistent (range, 3.33 +/- 0.15-3.75 +/- 0.04ns). By adding 10% of blood to samples, fluorescence intensities decreased to
According to the news editors, the research concluded: "Fluorescence-lifetime imaging with GSA-RhodG depicted ovarian cancer lesions, which were invisible in intensity images, in hemorrhagic ascites."
For more information on this research see: Fluorescence-lifetime molecular imaging can detect invisible peritoneal ovarian tumors in bloody ascites. Cancer Science, 2014;105(3):308-314. Cancer Science can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Cancer Science - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1349-7006)
The news editors report that additional information may be obtained by contacting T. Nakajima, National Cancer Institute, Mol Imaging Program, Center Canc Res, National Institutes of Health, Bethesda, MD 20892, United States. Additional authors for this research include K. Sano, K. Sato, R. Watanabe, T. Harada, H. Hanaoka, P.L. Choyke and H. Kobayashi (see also Ascites).
Keywords for this news article include: Cancer, Ascites, Bethesda, Maryland, Oncology, United States, Nanotechnology, Molecular Imaging, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC